Pacira BioSciences, Inc. PCRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total net product sales by Product | ||||||
| Bupivacaine liposome injectable suspension | $1.16M+4.4% | $1.11M-58.8% | $2.69M+430% | $508K-80.5% | $2.6M— | |
| EXPAREL | $143.27M-8.0% | $155.78M+11.4% | $139.9M-2.1% | $142.92M+4.7% | $136.53M-7.5% | |
| iovera° | $6.18M-11.8% | $7M+8.3% | $6.47M+15.7% | $5.59M+9.1% | $5.12M-20.6% | |
| ZILRETTA | $26.77M-18.8% | $32.98M+13.8% | $28.98M-7.5% | $31.33M+34.3% | $23.34M-29.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pacira BioSciences, Inc. break its business down?
- Pacira BioSciences, Inc. (PCRX) reports total net product sales by product across 4 parts — Bupivacaine liposome injectable suspension, EXPAREL, iovera° and ZILRETTA. Each is extracted from the segment footnotes and tracked over time.
- Where does Pacira BioSciences, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pacira BioSciences, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
